Eisai to divest rights for two therapies to Kaken

2024-04-02
·
交易
Pharmaceutical Technology
上市批准临床3期并购引进/卖出生物类似药
Eisai will continue to focus on creating and delivering products to target disease. Credit: mkfilm/Shutterstock.com.
Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in Japan, to Kaken Pharmaceutical.
Eisairansaction is valued at Y3.8bn ($25.10m).MerislonMyonalMyonalKaken Pharmaceutical
Merislon treats vertigo and equilibrium disturbances and Myonal is a muscle relaxant, which patients have used since their respective launches in 1969 and 1983.
The agreement stvertigos that Eisai will complete the traMyonalof marketing capabilities by March 2025, followed by manufacturing and marketing approval transfer.
The deal will not impact EisaiEisainsolidated financial forecast for 31 March 2024.
See Also:Eisai
China accepts Innovent-HUTCHMED’s endometrial cancer therapy NDA
Magazine: What’s next for AAV geneendometrial cancer?
The company stated: “Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’ disease areas, is the optimal choice to ensure they continue contributing to a greater number of patients.”
Eisai will continue to focus on creating and delivering products to target diseases with higher unmet medical needs such as neurology, oncology and global health.
Kaken is a research and development-driven pharmaceutical company that focuses on orthopaedics and dermatology.
Earlier this month, EEisaireceived approval for the amyloid beta-directed antibody LeqKaken(lecanemab-irmb) in China to treat mild cognitive impairment associated with Alzheimer’s disease (AD) and mild AD dementia.
Eisaibi, developed in partnership with BioArctic, will be available in the region in the third quarter of 2024. The approval in China is based on the international Phase III Clarity AD study.
Kaken will be responsible for distribution and information provision through expert medical representatives.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。